| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Probetacellulin; BTC; |
| Entrez GeneID | 685; |
| WB Predicted band size | 19kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from Internal of human BTC. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于BTC(Betacellulin)抗体的假设参考文献示例。请注意，这些文献为示例性质，实际研究请通过学术数据库查询：
1. **"Development of a Monoclonal Antibody Against Betacellulin for Diabetes Research"**
- 作者：Smith J, et al.
- 摘要：本研究开发了一种高特异性抗BTC单克隆抗体，通过体外实验证实其可抑制BTC诱导的β细胞增殖，为糖尿病治疗中的β细胞再生研究提供了新工具。
2. **"Targeting Betacellulin in Pancreatic Cancer with Neutralizing Antibodies"**
- 作者：Lee H, et al.
- 摘要：文章报道了一种中和性抗BTC抗体，可阻断BTC/EGFR信号通路，抑制胰腺癌小鼠模型中的肿瘤生长和转移，提示其潜在抗癌应用。
3. **"Betacellulin Antibody-Based Therapy Attenuates Liver Fibrosis in Murine Models"**
- 作者：Wang Y, et al.
- 摘要：研究发现抗BTC抗体可通过调节肝星状细胞活性减轻纤维化进程，为肝病治疗提供了新的分子靶点。
4. **"Role of Betacellulin Autoantibodies in Type 1 Diabetes Pathogenesis"**
- 作者：Garcia R, et al.
- 摘要：首次在1型糖尿病患者血清中检测到抗BTC自身抗体，提示其可能通过干扰β细胞修复参与疾病进展。
**备注**：BTC(Betacellulin)研究多聚焦于其在组织修复和肿瘤中的作用，直接针对其抗体的文献较少。建议扩大检索关键词(如"Betacellulin inhibition"或"BTC signaling")，并查阅《Diabetes》《Cancer Research》等期刊近年论文。
**Background of BTC Antibodies**
BTC (Betacellulin), a member of the epidermal growth factor (EGF) family, is a protein implicated in cellular proliferation, differentiation, and tissue repair. It binds to EGFR (HER1) and other ErbB receptors, activating downstream signaling pathways like MAPK and PI3K-AKT, which regulate critical biological processes. Dysregulation of BTC is linked to pathologies such as cancer, diabetes, and inflammatory disorders, making it a target for therapeutic and diagnostic research.
BTC antibodies are tools designed to detect, neutralize, or modulate BTC activity. Developed as monoclonal or polyclonal forms, these antibodies are utilized in research to study BTC expression, localization, and function in diseases. For instance, they enable BTC detection in tissues (via immunohistochemistry) or quantify its levels in biological fluids (via ELISA). Therapeutically, anti-BTC antibodies are explored for blocking oncogenic signaling in cancers overexpressing BTC or ErbB receptors, potentially inhibiting tumor growth.
Challenges include ensuring antibody specificity to avoid cross-reactivity with other EGF family members and optimizing delivery for clinical applications. Current research also focuses on bispecific antibodies or antibody-drug conjugates to enhance efficacy. Overall, BTC antibodies represent a promising avenue for understanding disease mechanisms and developing targeted therapies, particularly in oncology and regenerative medicine.
(Word count: 249)
×
